Market Place
Sourcing Support
Alpha Cognition Announces Partial Over-Allotment Option Exercise
16 Dec 2024 //
BUSINESSWIRE
Alpha Cognition Announces Voluntary Delisting from CSE
12 Dec 2024 //
BUSINESSWIRE
Alpha Announces Positive Data in Traumatic Brain Injury
11 Dec 2024 //
BUSINESSWIRE
Alpha Cognition Reports Q2 & H1 2024 Financial Results, Update
15 Nov 2024 //
BUSINESSWIRE
Alpha Cognition Prices $50M Public Offering, Lists on Nasdaq
12 Nov 2024 //
BUSINESSWIRE
Alpha Cognition Announces Appointment of VP Finance and Accounting
21 Oct 2024 //
BUSINESSWIRE
Alpha Cognition Receives Allowance For ZUNVEYL™ Patent
15 Oct 2024 //
BUSINESSWIRE
Alpha Cognition Announces Change of Officer
03 Oct 2024 //
BUSINESSWIRE
Alpha Cognition Completes $4.545M Convertible Note and Warrants
24 Sep 2024 //
BUSINESSWIRE
Alpha Cognition Receives Patent Allowance For ZUNVEYL In Alzheimer`s
19 Aug 2024 //
BUSINESSWIRE
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
13 Aug 2024 //
BUSINESSWIRE
Alpha Cognition Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
BUSINESSWIRE
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat AD
30 Jul 2024 //
BUSINESSWIRE
Alpha Cognition Announces Q1 2024 Results, Corporate Update
14 May 2024 //
BUSINESSWIRE
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results
03 Apr 2024 //
BUSINESSWIRE
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024
20 Mar 2024 //
BUSINESSWIRE
Alpha Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation
22 Feb 2024 //
BUSINESSWIRE
Alpha Cognition Provides Business Update
12 Feb 2024 //
BUSINESSWIRE
Alpha Cognition Announces Fourth Closing of Private Placement of the Offering
22 Dec 2023 //
BUSINESSWIRE
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062
07 Dec 2023 //
BUSINESSWIRE
Alpha Cognition Announces Amended Terms of Private Placement of the Offering
05 Dec 2023 //
BUSINESSWIRE
Alpha Cognition Announces Third Quarter Results
28 Nov 2023 //
BUSINESSWIRE
Alpha Cognition Announces Third Closing of Private Placement
08 Nov 2023 //
BUSINESSWIRE
Alpha Cognition Announces Second Closing of Private Placement
16 Oct 2023 //
BUSINESSWIRE
Alpha Cognition Announces Submission of NDA to the FDA for ALPHA-1062
27 Sep 2023 //
BUSINESSWIRE
Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results
22 Aug 2023 //
BUSINESSWIRE
Alpha Cognition Receives Notice of Allowance for Patent covering ALPHA-1062
14 Aug 2023 //
BUSINESSWIRE
Alpha Cognition Receives Army Medical Research Grant for Study onmTBI
07 Jun 2023 //
BUSINESSWIRE
Alpha Cognition Launches $6.5 Million Private Placement
30 May 2023 //
BUSINESSWIRE
Alpha Cognition Announces 1Q 2023 Results and Provides Corporate Update
30 May 2023 //
BUSINESSWIRE
Alpha Cognition to Present at the Planet MicroCap Showcase
05 Apr 2023 //
ACCESSWIRE
Alpha Cognition Closes Private Placement
16 Mar 2023 //
BUSINESSWIRE
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results
08 Mar 2023 //
BUSINESSWIRE
Alpha Cognition Provides Private Placement Update
06 Mar 2023 //
BUSINESSWIRE
Alpha Cognition Closes First Tranche of Private Placement
16 Feb 2023 //
BUSINESSWIRE
Alpha Cognition Announces $6.8 Million Private Placement
08 Feb 2023 //
BUSINESSWIRE
Alpha Cognition Announces Cancelation and Grant of Stock Options
19 Jan 2023 //
BUSINESSWIRE
Alpha Cognition Announces the Resignation of CMO Cedric O’Gorman, MD
06 Jan 2023 //
BUSINESSWIRE
Alpha Cognition Announces Withdrawal of Marketed Public Offering
28 Nov 2022 //
GLOBENEWSWIRE
Alpha Cognition Announces Marketed Offering
17 Nov 2022 //
GLOBENEWSWIRE
Alpha Cognition Announces Second Quarter 2022 Results
25 Aug 2022 //
BUSINESSWIRE
Alpha`s delayed release Alzheimer`s drug hits goal, teeing up approval filing
24 Aug 2022 //
FIERCEPHARMA
Alpha Cognition Announces Positive Topline Results from BE Study with ALPHA-1062
22 Aug 2022 //
BUSINESSWIRE
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062
22 Jun 2022 //
BUSINESSWIRE
Alpha Cognition Announces Successful Defense of EU Patent Covering ALPHA-0602
15 Jun 2022 //
BUSINESSWIRE
Alpha Cognition Announces Positive Data from PC Studies and more
13 Jun 2022 //
BUSINESSWIRE
Alpha Cognition Announces First Quarter 2022 Results and Company Update
31 May 2022 //
BUSINESSWIRE
Alpha Cognition Announces Grant of Stock Options
31 May 2022 //
BUSINESSWIRE
Alpha Cognition Announces Q4 and Full Year 2021 Results and Company Update
28 Apr 2022 //
BUSINESSWIRE
Alpha Cognition Announces Change of CFO, Grant of Stock Options
12 Apr 2022 //
BUSINESSWIRE
Alpha Cognition Announces Positive Data from PC Studies of ALPHA-0602 in ALS
29 Mar 2022 //
BUSINESSWIRE
Alpha Cognition Announces Positive Neuroprotection Data of ALPHA-1062
22 Feb 2022 //
BUSINESSWIRE
Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer
02 Dec 2021 //
BUSINESSWIRE
Alpha Cognition to begin its pivotal clinical trial for AZ`s disease
24 Sep 2021 //
PROACTIVEINVESTORS
Alpha Cognition Announces Pricing of Public Offering
23 Sep 2021 //
GLOBENEWSWIRE
Alpha Cognition Announces Overnight Marketed Offering
22 Sep 2021 //
GLOBENEWSWIRE
Alpha Cognition reports Acceptance of US FDA IND for ALPHA-1062 in Alzheimers
07 Sep 2021 //
BUSINESSWIRE
Alpha Cognition Reports Second Quarter of Fiscal 2021 Results
03 Sep 2021 //
BUSINESSWIRE
Alpha Cognition Reports Second Quarter of Fiscal 2021 Results
03 Sep 2021 //
BUSINESSWIRE
Alpha Cognition to Participate at the H.C. Wainwright 23rd Investment Conference
01 Sep 2021 //
BUSINESSWIRE
